Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Exploratory Evaluation of Novel Investigational Eye Movement Biomarkers to Track Ofatumumab Treatment Response in Canadian Patients With Active Relapsing-Remitting Multiple Sclerosis (ELIOS)

NCT06733922 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.

NCT NCT06733922
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06733922 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Exploratory Evaluation of Novel Investigational Eye Movement Biomarkers to Track Ofatumumab Treatment Response in Canadian Patients With Active Relapsing-Remitting Multiple Sclerosis (ELIOS)
Lead sponsor
Novartis Pharmaceuticals
Phase
Phase 4
Overall status
Recruiting
Start date
November 27, 2024
Completion date
November 30, 2028
Enrollment
224 (estimated)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

relapsing remitting multiple sclerosis (rrms)